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Type 2 diabetes is a common chronic condition associated with 
co-morbid hypertension and hyperlipidaemia. Multiple medicines 
are usually prescribed to manage these conditions. However, 
regimens containing multiple medicines are difficult to manage 
and their necessity may not be understood. As a result adherence 
can become a problem. This article discusses the impact of 
multiple medicines on adherence and the way adherence issues 
can be tackled during general practice consultations.    
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WHO suggests 
that over 50% 
of people do 
not take their 
medicines as 
prescribed
Type 2 diabetes (T2D) is associated with premature cardiovascular disease (CVD). About 70% of people with T2D also have 
hypertension or hyperlipidaemia as a co-morbid 
condition. The management of T2D can be complex 
and often multiple medicines are prescribed to manage 
an assortment of associated conditions. The National 
Institute for Health and Clinical Excellence (NICE) 
and randomised controlled trials such as the United 
Kingdom Perspective Diabetes Study (UKPDS)1 
and the Collaborative Atorvastatin Diabetes Study 
(CARDS)2 recommend intense pharmacological 
management of T2D. While the benefits of multiple 
medicines are established, the implications for the way 
that people manage their medicines are not as positive. 
Research indicates that regimens containing multiple 
medicines are dissatisfying and difficult to follow.3 
Therefore the implications of complex regimens, which 
contain multiple medicines for multiple conditions (as 
is often the case for people with T2D), are an important 
consideration. 
What is adherence?
People with T2D play an active role in the management 
of their condition(s), which includes the taking of 
medicines. The term ‘adherence’, when applied to 
medicines, describes taking medicines in a way that 
corresponds with the prescription given by a healthcare 
professional. This approach to defining 
medicine-taking behaviour also suggests 
that medicines are taken because a 
satisfactory level of information has 
been provided and there is a willingness 
to engage with the treatment plan 
(willingness to engage is a concept 
important for both the prescriber and 
those prescribed the medication). 
Other terms used to describe this behaviour include 
‘compliance’ which is a less patient-centered term and 
‘persistence’ which refers to medicine-taking over an 
extended period of time.
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T2D medicines 
are often 
proritised 
over CVD 
medicines
The World Health Organization suggests that over 
50% of people do not take their medicines as prescribed.4 
Unfortunately chronic illnesses such as T2D are 
associated with much lower levels of adherence. Also, 
adherence in T2D can depend on the type of treatment 
offered. A systematic review of research found that 
adherence to regimens containing oral hypoglycaemic 
agents (OHAs) alone was 36%-87% compared to 54%-
81% adherence in insulin-only regimens.5
Not adhering to medicines (non-adherence) in 
T2D includes a range of behaviours which are caused 
by different factors. For example people with T2D 
may take medication holidays, consume larger doses 
after perceiving an increase in symptoms, forget their 
medicines or reduce their medicine consumption to 
avoid side-effects. Such examples of non-adherent 
behaviour can be divided into:
•  intentional non-adherence;
•  non-intentional non-adherence.6
Intentional non-adherence is the result of decision-
making and is thought to be driven by perceptions 
about how necessary a medication may be and concerns 
about medicines (such as a fear of side-effects).7 Non-
intentional non-adherence reflects a person’s ability 
or skill at medicine-taking. The main reasons for non-
intentional non-adherence are forgetting or losing 
medicines and manual dexterity problems. Therefore, 
non-adherence can be accidental or the result of a 
reasoned decision-making process. Furthermore, a 
person with T2D may report both intentional and non-
intentional non-adherence to the same medication at 
different times.6 
Adherence to multiple medicines in T2D and CVD
Multiple medicines can lead to poor adherence and, 
conversely, reductions in the frequency of daily 
medication doses can improve adherence.8,9 A Scottish 
study of 2920 people prescribed OHAs found that one 
tablet per day led to better adherence in comparison to 
multiple daily doses.10 Other studies report that high 
numbers of angiotensin-converting enzyme inhibitors, 
beta-blockers and statins are also associated with lower 
adherence.11 Thus regimens containing multiple OHAs 
alongside medicines to manage CVD may be especially 
susceptible to low levels of adherence.
Research has found that T2D medicines are often 
proritised over CVD medicines.12 This study found 
that the threat of microvascular complications was 
heightened and T2D was perceived to be a permanent 
condition requiring long-term intense pharmacological 
management. For many the threat of macrovascular 
complications was not immediate and multiple 
medicines for CVD management were believed to be 
unnecessary. Many people with T2D did not recognise 
the necessity of the step-up approach to prescribing 
CVD medicines. Instead lifestyle modification 
was believed to be an appropriate prescription for 
hypertension and hyperlipidaemia management. Lipid-
lowering medicines were perceived to 
be the least important CVD medication 
prescribed. People with T2D were less 
concerned when these medicines were 
missed or forgotten and described testing 
their need for lipid-lowering medicines 
through temporary non-adherence or 
total cessation of medicines. Adherence 
decisions appear to be driven by characteristics 
of medicines, the way medicines are prescribed 
and perceptions about illness: CVD medicines are 
especially vulnerable.  
This is a concerning finding, as CVD is the 
largest cause of mortality for people with T2D. It is 
possible that the value placed on CVD medicines is 
due to low awareness levels or the need for additional 
information about macrovascular complications. A 
US survey assessed awareness of CVD risk among 
people with diabetes.13 Those surveyed were more 
aware of microvascular complications and 68% of 
people surveyed did not consider CVD to be a serious 
complication of diabetes. Only 18% of those surveyed 
cited taking prescription medicines as a method for 
reducing their cardiovascular risk.
Addressing adherence in general practice 
Identifying non-adherence
Identifying non-adherent behaviour can be difficult. 
A study revealed that doctors who knew their patients 
for 5 years or more were poor (i.e. no better than 
chance) at predicting non-adherent behaviour.14 The 
solution to this problem can be straightforward; 
rather than relying on intuition, research suggests that 
asking people about adherence and their medicines 
management is an effective way of identifying non-
adherence.15 
Approaching the topic of non-adherence is easiest 
if conversations about past behaviours and current 
perceptions of medicines are initiated. Questions such as 
“many people find it difficult to take these tablets, how 
do you find it?” or “which medicine do you dislike to 
take most?” can be used. The objective of this approach 
is to work towards honest disclosure of perceptions and 
discussions of past adherence behaviours. 
Identifying the type of non-adherence experienced is 
important, as this will determine the type of intervention 
required. A person may disclose intentional and non-
intentional non-adherence to the same medicines, so a 
multi-modal approach is a possibility. 
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Addressing non-intentional non-adherence 
A variety of strategies to enhance vigilance can 
be used to improve forgetting, manual dexterity 
problems, inattentiveness and other forms of non-
intentional adherence. Memory aids, such as Doset 
boxes and reminders many help those who are prone 
to forgetting their medicine. Self-monitoring has been 
suggested to improve non-intentional non-adherence 
in hypertension,16 however, the use of self-monitoring 
in diabetes is debated. Eisen and colleagues suggested 
that the most important action that a prescriber can 
take in addressing non-adherence difficulties, such 
as forgetting, is to select medications that permit the 
lowest daily prescribed dose frequency”.3 Therefore, 
combination drugs or slow-release medicine (such as 
metforminSR) may reduce the regimen complexities 
that challenge people with T2D.  
Addressing intentional non-adherence
Finding solutions to intentional non-adherence can 
be problematic, as this type of adherence involves a 
decision not to take a medicine as prescribed. Adherence 
cannot be forced and people can often be resistant 
to overt persuasion techniques. However, exploring 
the beliefs behind decisions not to take medicines as 
prescribed can be a way of ensuring that decisions are 
not made based on misinformation or false premises. 
Beliefs about treatment are key to understanding 
adherence decisions; thus beliefs can be psychological 
barriers to improved health. This approach may include 
asking people about their worries or feelings of sadness 
and dissatisfaction. 
Prescribers are faced with the task of acknowledging, 
understanding and then acting upon beliefs. One of 
the most accessible methods of action is to provide 
information tailored to beliefs or discussions 
surrounding adherence. For example, communicating 
CVD risks is vital, especially as the severe consequences 
of hypertension and hyperlipidaemia 
are often poorly understood by 
people with T2D. Discussing long-
term healthcare goals, re-evaluating 
treatment aims and developing a plan 
are additional tools for addressing 
decisions and beliefs. 
Addressing emotional concerns 
is important, and recognising any 
need for referral is vital. This is 
especially important because the rate 
of psychological morbidity is higher for people with 
T2D than it is in the general population, and managing 
co-morbid psychiatric conditions on top of co-morbid 
physical conditions is possibly too complex and 
difficult for a typical time-limited GP consultation.
Uncovering beliefs about treatment and illness, 
providing additional information and addressing 
emotional distress, may positively influence adherence. 
However, the benefits of this approach may extend to 
enhancing communication, improving the therapeutic 
relationship, increasing patient satisfaction or leading 
to a change in prescribing practices (to match patient 
preferences) where a clinically viable alternative is 
available.
New NICE recommendations on adherence
NICE recently published guidelines as part of 
a consultation on medicine concordance and 
adherence.17 The draft consultation suggests that 
prescribers should aim to meet the wishes of their 
patients, even if this means prescribing a sub-optimal 
regimen; however, informed consent is vital. The 
advice given to prescribers is to: 
“Be aware that a shared decision may mean an 
agreement not to prescribe a medication or for 
the patient to stop taking a medication. If in the 
healthcare professional’s view this may have an 
adverse effect, then this must be recorded”.17
Shared decision-making and informed adherence 
are integral to this approach. The prescriber’s role is 
to provide information that will enhance knowledge 
about treatment, promote understanding and allow for 
a informed adherence decision to be made. To identify 
information and support needs, existing beliefs about 
treatment and illness should be considered. For 
example, unlike painkillers, medicines used to treat 
T2D do not lead to immediate symptom relief (as 
T2D is usually asymptomatic). The lack of immediate 
benefits and symptom relief may lower motivation to 
adhere and levels of medicine-taking may fall over 
time. Understanding the way a person appraises their 
illness is important for understanding when additional 
information or counselling is required. Providing 
information in line with, or tailored to beliefs 
(particularly beliefs based on false premises), will 
ensure that any decision made is fully informed.
Summary 
Adherence to T2D medicines is often complicated by co-
morbid hypertension and hyperlipidaemia management. 
Evidence indicates that CVD management is not a 
priority for some people with T2D. Adherence cannot 
be forced but, where decisions not to take medicines are 
apparent, healthcare providers have the opportunity to 
ensure that non-adherence is a fully informed decision. 
Facilitating informed decision-making can allow 
people with T2D to take full control and responsibility 
for the way that their medicines are managed. 
The severe 
consequences of 
hypertension and 
hyperlipidaemia 
are often poorly 
understood by 
people with T2D
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